NCT05262764Completed
Post Marketing Surveillance (PMS) of JARDIANCE in Chronic Heart Failure (CHF)
Post Marketing Surveillance on Long Term Drug Use of JARDIANCE® Tablets in Patients With Chronic Heart Failure in Japan
Source: ClinicalTrials.gov · Last updated 24 Mar 2026
Brief summary (registry, in English)
Study objective is to investigate the safety and effectiveness of long-term daily use of JARDIANCE® Tablets in patients with chronic heart failure (CHF) under real-world use.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 1200 (actual)
- First submitted
- 1 Mar 2022
- Start date
- 15 Apr 2022
- Primary completion date
- 21 Jun 2024
- Lead sponsor
- Boehringer Ingelheim
- Diseases
- Heart failure
- NCT number
- NCT05262764
What you commit to
- Study type: Observational
- Participants enrolled: 1200
- From 15 Apr 2022 to the primary completion date, 21 Jun 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- None
Who the study is looking for
- Patients with chronic heart failure (CHF) failure who are prescribed with JARDIANCE® Tablets in Japan
- Patients who have never been treated with Empagliflozin (including treatment for type 2 diabetes mellitus (T2DM)) before enrolment
Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Nippon Boehringer Ingelheim Co., Ltd. Coordinator of this site? Confirm its status | Tokyo | Japan | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.